Corcept Therapeutics: New All-Time High Due to Strong Growth in Cortisol Medications
Reading Time: 3 minutes
Corcept Therapeutics researches and develops medications that regulate the effects of the stress hormone cortisol in the body. This allows for the treatment of severe metabolic diseases, oncological, and psychiatric disorders. In the second quarter, revenue increased by 32%, attributed to the established Cushing's syndrome medication Korlym and the successful market launch of the new cancer drug Lifyorli. Management raised the revenue forecast for 2026 to 51%. By 2030, annual revenues could reach $3 to $5 billion. Within the notably...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
